Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × OTHER × Crizotinib × Clear all

Phase

Phase 2 20 Phase 1 10 Phase EARLY_PHASE1 1 Phase 4 1 Phase 3 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

INDUSTRY 4 OTHER 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lung Neoplasms 1

Interventions

Cyclophosphamide 205 Radiotherapy 143 Carboplatin 126 pembrolizumab 123 Gemcitabine 122 Nivolumab 112 Paclitaxel 111 Cisplatin 99 fludarabine 96 Dexamethasone 91 Lenalidomide 85 Docetaxel 83 Rituximab 81 Bevacizumab 78 Capecitabine 77 fludarabine phosphate 74 Temozolomide 74 Cytarabine 71 Oxaliplatin 69 Etoposide 66 Irinotecan 63 Filgrastim 63 venetoclax 62 Doxorubicin 61 Melphalan 60 Peripheral Blood Stem Cell Transplantation 59 Fluorouracil 56 durvalumab 53 Cetuximab 52 Bortezomib 52

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Massachusetts General Hospital

Phase 1/2 Unknown

Lung Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡